A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia
NCT ID: NCT03485053
Last Updated: 2021-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
49 participants
INTERVENTIONAL
2018-11-29
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IOP Injection / MPB-1514
Administered IV infusion
IOP Injection / MPB-1514
Dilute with 5% Dextrose solution (D5W)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IOP Injection / MPB-1514
Dilute with 5% Dextrose solution (D5W)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject with IDA but not secondary to any malignancy or renal failure requiring dialysis.
3. Hb levels \<11.0 g/dL, Ferritin levels \<200 ng/dL, Transferrin saturation (TSAT) \< 20% at the Screening Visit.
4. Subject must have the ability to provide written, personally signed, and dated informed consent to participate in the study.
5. Subject must have an understanding, ability, and willingness to comply fully with study procedures and restrictions and to be available for clinic visits and follow-up procedures.
6. Female subject of child-bearing potential who is sexually active must use an effective method of birth control for at least one month prior to screening and agree to use an effective method of birth control until completion of participation in the study.
Exclusion Criteria
2. Subject with a history of intravascular hemolysis.
3. Subject receiving any erythropoiesis-stimulating agent (ESA) therapy within 4 weeks prior to screenin.
4. Subject with a known sensitivity to any i.v. iron formulation
5. Subject with C-reactive protein \> 20 mg/dL.
6. Subject with HBV, HCV, HIV.
7. Subject with known malignancy or severe renal failure requiring dialysis.
8. Subject with a recent (within 1 year of study drug administration) drug or alcohol abuse (including cannabis products) as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Diagnostic Criteria for Drug and Alcohol Abuse.
9. Subject averages an intake of more than 21 units of alcohol per week (≥ 3 drinks per day) for men and 14 units of alcohol per week (≥ 2 drinks per day) for women (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).
10. Subject who has smoked or used smoking cessation or nicotine containing products (including but not limited to e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months of the first dose of study drug.
11. Subject with any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol.
12. Subject with psychiatric disorder precluding the understanding of information on study related topics or giving informed consent.
13. Subject who has received another investigational agent within 4 weeks prior to screening.
14. Subject undergoing major surgery or physical trauma within 90 days or with major burn injury covering \> 20% of total body surface area.
15. Female subject who is pregnant or breast feeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MegaPro Biomedical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Fishbane, MD
Role: PRINCIPAL_INVESTIGATOR
North Shore University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North America Research Institute
Azusa, California, United States
Valley Renal Medical Group
Northridge, California, United States
Whittier Internal Medicine and Nephrology Medical Group
Whittier, California, United States
South Florida Research Institute
Lauderdale Lakes, Florida, United States
North Shore University Hospital Lab
Manhasset, New York, United States
Clinical Research Development Associates
Springfield Gardens, New York, United States
Northeast Clinical Research Center
Bethlehem, Pennsylvania, United States
Southwest Houston Research Ltd.
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IOP-CT-004
Identifier Type: -
Identifier Source: org_study_id